Literature DB >> 22209020

High YKL-40 levels predict mortality in patients with type 2 diabetes.

Frederik Persson1, Camilla Noelle Rathcke, Mari-Anne Gall, Hans-Henrik Parving, Henrik Vestergaard, Peter Rossing.   

Abstract

AIMS: We determined levels of the inflammatory marker YKL-40 in a population of patients with type 2 diabetes (T2D) and investigated the association with mortality.
METHODS: In a prospective observational follow-up study, 290 patients with T2D, normoalbuminuria (n=177), microalbuminuria (n=71) and macroalbuminuria (n=42) were followed for a median (range) of 17.2 (0.2-23.0) years. Serum YKL-40 concentration was determined at baseline.
RESULTS: Baseline median (IQR) YKL-40 level was 46ng/ml (36-67) in patients with normoalbuminuria, 61ng/ml (43-114) in microalbuminuric patients, and 81.5ng/ml (60-157) in patients with macroalbuminuria, p<0.001. During follow-up 189 patients (65.2%) died, 119 (41.0%) from cardiovascular causes. All-cause mortality was increased in patients with YKL-40 levels in the second and third tertile (hazard ratios (95% CI) compared with the first tertile, (1.50 (1.03-2.19), p=0.034, and 2.88 (2.01-4.12), p<0.001). This association persisted after adjustment for cardiovascular risk factors but was attenuated after additional adjustment for urinary albumin excretion rate and glomerular filtration rate. Cardiovascular mortality was increased with YKL-40 levels in the third tertile compared with the first tertile, (2.70 (1.78-4.08)), p<0.001. This association was diminished after adjustment for covariates.
CONCLUSIONS: In patients with T2D and increasing albuminuria high YKL-40 levels predict all-cause mortality.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209020     DOI: 10.1016/j.diabres.2011.12.008

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  10 in total

1.  A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes.

Authors:  Michelle J Pena; Andreas Heinzel; Georg Heinze; Alaa Alkhalaf; Stephan J L Bakker; Tri Q Nguyen; Roel Goldschmeding; Henk J G Bilo; Paul Perco; Bernd Mayer; Dick de Zeeuw; Hiddo J Lambers Heerspink
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

Review 2.  Diabetic nephropathy: What does the future hold?

Authors:  R M Montero; A Covic; L Gnudi; D Goldsmith
Journal:  Int Urol Nephrol       Date:  2015-10-05       Impact factor: 2.370

3.  Chitinase-3-like 1 is a biomarker of acute kidney injury and mortality in paediatric severe malaria.

Authors:  Andrea L Conroy; Michael T Hawkes; Robyn Elphinstone; Robert O Opoka; Sophie Namasopo; Christopher Miller; Chandy C John; Kevin C Kain
Journal:  Malar J       Date:  2018-02-15       Impact factor: 2.979

4.  Estimation of YKL-40 Levels in Serum and Gingival Crevicular Fluid in Chronic Periodontitis and Type 2 Diabetes Patients among South Indian Population: A Clinical Study.

Authors:  Prathush Ajit Kumar; Krishna Kripal; Kavita Chandrasekaran; Sushma Reddy Bhavanam
Journal:  Contemp Clin Dent       Date:  2019 Apr-Jun

5.  Estimation of YKL-40 Acute-Phase Protein in Serum of Patients with Periodontal Disease and Healthy Individuals: A Clinical-Biochemical Study.

Authors:  Vinay Chavan; Srinu Sabavath; C Hemachandra Babu; Laxman Boyapati
Journal:  Contemp Clin Dent       Date:  2019 Apr-Jun

6.  YKL-40 acts as an angiogenic factor to promote tumor angiogenesis.

Authors:  Rong Shao
Journal:  Front Physiol       Date:  2013-05-28       Impact factor: 4.566

7.  Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease.

Authors:  Dennis B Holmgaard; Lone H Mygind; Ingrid L Titlestad; Hanne Madsen; Svend Stenvang Pedersen; Julia S Johansen; Court Pedersen
Journal:  BMC Pulm Med       Date:  2013-12-30       Impact factor: 3.317

Review 8.  Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease.

Authors:  Michelle J Pena; Harald Mischak; Hiddo J L Heerspink
Journal:  Diabetologia       Date:  2016-06-25       Impact factor: 10.122

9.  Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy.

Authors:  Obiageli Offor; Netanya Utay; David Reynoso; Anoma Somasunderam; Judith Currier; Jordan Lake
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

Review 10.  Chitinase-3 like-protein-1 function and its role in diseases.

Authors:  Ting Zhao; Zhongping Su; Yingchang Li; Xiaoren Zhang; Qiang You
Journal:  Signal Transduct Target Ther       Date:  2020-09-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.